Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the current treatment landscape for AML (Vyxeos, Idhifa/Tibsovo) and where Venclexta could fit in after recently gaining FDA accelerated approval

Ticker(s): JAZZ, RHHBY, ABBV, AGIO

Who's the expert?

Name: Dr Gabriel Ghiaur - MD

Institution: Johns Hopkins University

  • Medical oncologist affiliated with the Sidney Kimmel Comprehensive Cancer Center and an assistant professor at Johns Hopkins University.
  • Currently manages 80-100 patients per year with AML; sees 50 new patients a year out of 300 in his group.
  • Physician-scientist whose primary interest is normal and malignant hematopoiesis; research has translational potential in stem cell therapeutics, as well as acute leukemia.

Interview Questions
Q1.

Please describe your clinical practice; roughly how many patients with AML do you currently manage?

Added By: c_admin
Q2.

Have you prescribed Jazz Pharma's Vyxeos and/or Agios’ Idhifa/Tibsovo?

Added By: c_admin
Q3.

What are your thoughts on the FLT3 inhibitors (midostaurin and gilteritinib)? When do you test for FLT3 mutations and where do you see them best fitting into the treatment plan (maintenance? relapse?).

Added By: thealchemist

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.